| Document |
Document Title |
|
WO/2012/177497 |
A method and corresponding pharmaceutical composition to inhibit neuropathic pain by injecting intrathecally into a mammalian subject a neuropathic pain-inhibiting amount of a phosphatase falling within E.C. 3.1.3.x, more specifically a ...
|
|
WO/2012/174666 |
The present invention provides methods and uses for the diagnostic of a subject predisposed or suspected of developing a neurodegenerative disease or suffering from a neurodegenerative disease. The present invention also relates to metho...
|
|
WO/2012/175434 |
A pharmaceutical formulation for intravenous (IV) administration comprising 2-(S)-(4-Fluoro-2- methyl-phenyl)-piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methyl-amide or a pharmaceutically acceptable salt ...
|
|
WO/2012/176763 |
Provided is a therapeutic agent for conditions involving the cholinergicity of the central nervous system (CNS) and/or peripheral nervous system (PNS), conditions involving smooth muscle contraction, endocrine conditions, conditions invo...
|
|
WO/2012/175714 |
The present invention relates to rectal administration of phenylbutyrate for treating a motor neuron disease, such as, for example, spinal muscular atrophy or a metabolic disease such as, for example, an urea cycle disorder, related meth...
|
|
WO/2012/176172 |
The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke. The treatment involves administration of a PSD-95 inhibitor and performing reperfusion therapy (e.g., by administra...
|
|
WO/2012/175018 |
A traditional Chinese medicine composition for promoting nerve regeneration and the preparation method and use thereof. The traditional Chinese medicine composition consists of fleece-flower root, ginseng and ginkgo leaf; alternatively, ...
|
|
WO/2012/176061 |
The disclosure relates to Compounds of Formula (I) and pharmaceutically acceptable derivatives thereof, where R1, R4, R8, R9, and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a phar...
|
|
WO/2012/175894 |
The invention relates to a pharmaceutical composition for treating dependency in human beings, including the following two active principles: cyproheptadine, which is selected to be a compound having an antagonistic activity against the ...
|
|
WO/2012/176438 |
[Problem] To provide a novel substance which can exert a sedating effect safely and effectively through being vaporized and inhaled. [Solution] A sedative agent for vaporization and inhalation, which comprises 3-methoxy-5-methylphenol as...
|
|
WO/2012/177896 |
Compounds of Formula (I) are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for trea...
|
|
WO/2012/177738 |
PDE10 inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit PDE10 are also disclosed.
|
|
WO/2012/178015 |
Provided herein are compounds that inhibit or partially inhibit the activity of leucine rich repeat kinases. Also provided herein are methods of treatment of CNS disorders comprising administration of inhibitors of leucine rich repeat ki...
|
|
WO/2012/176061 |
The disclosure relates to Compounds of Formula (I) and pharmaceutically acceptable derivatives thereof, where R1, R4, R8, R9, and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a phar...
|
|
WO/2012/176659 |
The present invention provides a simple and efficient method for producing safer chemical compounds which prevent and ameliorate conditions and ailments caused by a deterioration in brain function and are suitable for use in medicines an...
|
|
WO/2012/177997 |
The present disclosure provides technologies relating to lysosomal activation. The disclosure provides several strategies for increasing level and/or activity of lysosomal enzyme, and furthermore demonstrates the surprising applicability...
|
|
WO/2012/175531 |
The present invention relates to 4-((1 R,3S)-6-chloro-3-phenyl-indan-1 -yl)-1,2,2-trimethyl- piperazine and the salts thereof with activity at dopamine D1 and D2 receptors as well as the serotonin 5HT2 receptor for the treatment of disea...
|
|
WO/2012/177565 |
The present disclosure relates to regulation of macrophage activation by delivering of miRNAs, for example miR-125b or anti-miR-125b, to macrophages. For example, in some embodiments, macrophage activation can be elevated or reduced by a...
|
|
WO/2012/178022 |
The present disclosure provides methods for reducing axonal and/or synaptic degradation in neurons by modulating sterile α/Armadillo/Toll-Interleukin receptor homology domain protein (SARM) activity and/or expression.
|
|
WO/2012/176066 |
The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compoun...
|
|
WO/2012/177708 |
The present invention concerns paiiperidone oleate, a solid state form thereof, pharmaceutical compositions comprising paiiperidone oleate, the use of paiiperidone oleate for the treatment of schizophrenia, and processes for preparing pa...
|
|
WO/2012/177618 |
The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in whic...
|
|
WO/2012/175973 |
The invention provides compositions comprising a Histone Deacetylase 6 (HDAC6) inhibitor and an AKT inhibitor, pharmaceutical compositions/formulations and kits of parts comprising the same; optionally further comprising one or more anti...
|
|
WO/2012/178122 |
Methods and compositions for generating nonhuman disease models through splicing modulation.
|
|
WO/2012/174730 |
The present invention discloses ZYJ-D08a and its epimer ZYJ-D08ae as histone deacetylase inhibitors in pharmacy field, and their preparative methods and medical use for inhibiting tumor. ZYJ-D08a and its epimer ZYJ-D08ae are represented ...
|
|
WO/2012/172449 |
Compound and pharmaceutically acceptable salts of the compound are disclosed, wherein the compound has the structure (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthes...
|
|
WO/2012/173214 |
The purpose of the present invention is to provide: a compound having a monoamine reuptake inhibition activity or the like; and a prophylactic or therapeutic agent for depression, anxiety, attention deficit-hyperactivity disorder, postme...
|
|
WO/2012/172090 |
The present invention relates to certain chromane-like cyclic prenylfiavonoids, in particular the compounds of formulae (I), (II) and (III) as described and defined herein, for use in the treatment or prevention of a neurological disorde...
|
|
WO/2012/173174 |
Provided is a compound represented by general formula (I) and having an excellent GPR119 agonistic activity, or a pharmaceutically acceptable salt thereof. [In general formula (I), m1 represents an integer of 0-2; m2 represents an intege...
|
|
WO/2012/174552 |
The present invention concerns methods of using Cathepsin S inhibitors and compounds of Formula I that are inhibitors of cathepsin S in treating CNS disorders, diseases, and injuries, particularly neurodegenerative conditions. The presen...
|
|
WO/2012/171653 |
The present invention relates to the efficient treatment of an individual afflicted with attention deficit hyperactivity disorder (ADHD), the instant treatment comprising administering to the individual an effective amount of sarizotan o...
|
|
WO/2012/173442 |
The present invention relates to a composition which contains, as an active ingredient, bee venom phospholipase A2 (phospholipase A2, Group III sPLA2) separated from bee venom. The composition controls the expression of AKT or p-38 MAPK ...
|
|
WO/2012/172093 |
The invention relates to heterocyclic derivatives of formula I, wherein the substituents R1-R5 and R11 are as defined in the claims, as well as their pharmaceutically acceptable salts. The invention further relates to a process for the p...
|
|
WO/2012/173442 |
The present invention relates to a composition which contains, as an active ingredient, bee venom phospholipase A2 (phospholipase A2, Group III sPLA2) separated from bee venom. The composition controls the expression of AKT or p-38 MAPK ...
|
|
WO/2012/174362 |
The invention provides compounds capable of acting as antagonists at cannabanoid receptors according to the following formula: Such compounds may be used to treat conditions for which the cannabinoid receptor system has been implicated, ...
|
|
WO/2012/173442 |
The present invention relates to a composition which contains, as an active ingredient, bee venom phospholipase A2 (phospholipase A2, Group III sPLA2) separated from bee venom. The composition controls the expression of AKT or p-38 MAPK ...
|
|
WO/2012/173319 |
The present invention relates to a composition containing bee venom phospholipase A2 (group Ⅲ sPLA2)isolated from bee venom as an active ingredient, which enables the treatment of neurodegenerative disorders by regulating the expressio...
|
|
WO/2012/173163 |
Crushed cells are obtained by culturing gram-negative bacteria and physically crushing the gram-negative bacterial cells, contain all components that contain immunity-activating components of the cells, and contain LPS having a molecular...
|
|
WO/2012/173808 |
The invention relates to the treatment of disorders associated with elevated myo-inositol levels in brain, in particular behavioural and neuropsychiatry disorders such as dementia, mild Alzheimer's disease, mild cognitive impairment or b...
|
|
WO/2012/174123 |
The present specification discloses methods of treating a psychological trauma in an individual using botulinum toxins and/or a Targeted Exocytosis Modulator, and compositions thereof.
|
|
WO/2012/173952 |
The disclosure relates to piperazine derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to inhibitors of NADPH-oxidase.
|
|
WO/2012/171974 |
The present invention relates to tadalafil, pharmaceutically acceptable salts and solvates thereof, for use in the prevention or treatment of dementia and Alzheimer's disease in a geriatric patient, wherein tadalafil is administered at a...
|
|
WO/2012/173219 |
The present invention relates to a compound having an excellent DGAT inhibitory activity and an excellent antifeeding activity or a pharmacologically acceptable salt thereof. A compound represented by general formula (I) [wherein R1 repr...
|
|
WO/2012/173184 |
[Problem] To provide a LELIA (Liposome-based Enzyme-Linked ImmunoAssay) method using recombinant proteoliposomes, wherein the baseline is sufficiently lowered, allowing the measurement of trace substances that were previously difficult t...
|
|
WO/2012/173850 |
The present invention provides novel mGlu2 agonists useful in the treatment of bipolar disorder, schizophrenia, and generalized anxiety disorder.
|
|
WO/2012/171231 |
The invention provides the use of a protein acrosin for the treatment of cancer and depression and the preparation method thereof. Said acrosin is isolated from animal semen or animal semen freeze-dried powder.
|
|
WO/2012/168657 |
Industrial process for synthesis and crystalline form I of the compound of formula (I): and the crystalline form I of the associated free base. Medicaments.
|
|
WO/2012/168710 |
The invention provides compounds of formula (I): Said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.
|
|
WO/2012/170899 |
The invention provides a method and compositions for treating a subject with a lysosomal storage disease such as gaucher disease, by administering to a subject with a lysosomal storage disease a therapeutically effective amount of compos...
|
|
WO/2012/170917 |
Methods for deterring microglia-mediated neurotoxicity in a human or non-human animal subjects comprising the step of inhibiting or blocking the intermediate-conductance calcium-activated potassium channel Kvl.3 in microglia, such as in ...
|
